United States Food and Drug Administration
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
FDA rejects Defender’s motion sickness treatment
United States Food and Drug Administration, Safety, Effectiveness
Fake versions of Novo Nordisk’s Ozempic linked to 3 dangerous hypoglycemia cases in US: Reuters
Hypoglycemia, Case (situation), Ultrasonography, Nordisk’s, United States Food and Drug Administration
Sarepta shares PhII data for next-gen exon skipping drug, but regulatory pathway is unclear
Regulatory Pathway, Sarepta, next-generation exon-skipping drug, United States Food and Drug Administration, Approved, Muscular Dystrophy, Duchenne, gene therapy, Sarepta’s gene therapy
Lilly’s Donanemab Poised for FDA Decision amid Embraced Alzheimer’s Disease Competition
Alzheimer’s Disease, Donanemab, United States Food and Drug Administration, Lilly’s